{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with \\<5% plasma cells, \\<1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.","groups":[{"description":"Melphalan 100 mg/m\\^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily","id":"OG000","title":"No Bortezomib"},{"description":"Bortezomib (Level 1) 1.0 mg/m\\^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m\\^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily","id":"OG001","title":"Bortezomib 1.0 mg/m^2"},{"description":"Bortezomib (Level 2) 1.5 mg/m\\^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily","id":"OG002","title":"Bortezomib 1.5 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was per protocol.","reportingStatus":"POSTED","timeFrame":"Baseline through Day 180, with assessments at Day 90 and Day 180","title":"Number of Patients Reaching Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"participants"}